Rilmazafone (CAS 99593-25-6) – Hypnotic Sedative Anxiolytic API

Rilmazafone (CAS 99593-25-6) is a high-purity pharmaceutical API classified as a potent hypnotic sedative, featuring a triazoloazepine molecular structure that acts as a benzodiazepine receptor agonist. It exerts rapid hypnotic, sedative, and anxiolytic effects by enhancing gamma-aminobutyric acid (GABA) neurotransmission in the central nervous system—facilitating sleep onset, improving sleep quality, and reducing anxiety without significant residual sedation. This API presents as a white to off-white crystalline powder with excellent oral bioavailability and stability, supporting convenient oral dosage form development.

It caters to the core needs of CNS drug manufacturers, sedative-hypnotic formulation developers, and clinical supply chains. Widely applied in developing treatments for insomnia (including difficulty falling asleep and maintaining sleep) and anxiety-related sleep disorders, it aligns with demand for safe, fast-acting hypnotic therapies. Produced under strict GMP standards, each batch undergoes rigorous purity, dissolution, and potency testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing reliable sleep disorder solutions, this Rilmazafone API serves as a critical raw material for advancing sedative-hypnotic medication development.